43P Pre-clinical evaluation of potent and orally bioavailable next-generation inhibitors targeting the family of mutants that drive oncogenic BRAF dimer formation
Titel:
43P Pre-clinical evaluation of potent and orally bioavailable next-generation inhibitors targeting the family of mutants that drive oncogenic BRAF dimer formation
Auteur:
Han, Y-C. Ng, P.Y. Schulz, R. Yang, S.N. Lelo, A. Ogawa, L.S. O'Connor, M. Ishiyama, N. Jewett, I. Romashko, D. Salomatov, A. Thakur, S. Smith, S. Buck, E. Roberts, C. Lucas, M. Lin, T-A.